Summary by Futu AI
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on May 6, 2024, as part of a larger 12-month buyback plan worth up to DKK 20 billion, which began on February 6, 2024. From May 7 to August 5, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.2 billion. As of May 31, 2024, the company has repurchased 9,366,795 B shares at an average price of DKK 865.36, totaling DKK 8,105,649,158. The recent transactions from May 27 to May 31, 2024, resulted in the acquisition of 196,393 B shares for a combined value of DKK 180,735,500, bringing the total shares repurchased under the program to 632,545. Novo Nordisk now holds 10,732,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.